RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

Benzinga · 2d ago
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.